Voya Investment Management LLC Boosts Stock Position in CRISPR Therapeutics AG $CRSP

Key Points

• Voya Investment Management LLC raised its stake in CRISPR Therapeutics AG by 60.2%, bringing its total shares to 13,870, valued at approximately $472,000.
• The company's Director, Simeon George, acquired 989,812 shares at an average price of $52.03, increasing his holdings by 133.69%.
• CRISPR Therapeutics' stock recently opened at $61.67, reflecting a 2.2% increase, with a significant market cap of $5.61 billion.

Voya Investment Management LLC raised its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 60.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,870 shares of the company's stock after acquiring an additional 5,210 shares during the period. Voya Investment Management LLC's holdings in CRISPR Therapeutics were worth $472,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the stock. Bayforest Capital Ltd acquired a new position in CRISPR Therapeutics in the first quarter valued at $423,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in CRISPR Therapeutics by 182.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,952,751 shares of the company's stock valued at $66,452,000 after acquiring an additional 1,262,560 shares in the last quarter. Woodline Partners LP boosted its stake in CRISPR Therapeutics by 34.3% in the first quarter. Woodline Partners LP now owns 136,483 shares of the company's stock valued at $4,645,000 after acquiring an additional 34,883 shares in the last quarter. Millennium Management LLC boosted its stake in CRISPR Therapeutics by 6,769.1% in the first quarter. Millennium Management LLC now owns 583,733 shares of the company's stock valued at $19,864,000 after acquiring an additional 575,235 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new position in CRISPR Therapeutics in the first quarter valued at $861,000. Institutional investors and hedge funds own 69.20% of the company's stock.

Insider Transactions at CRISPR Therapeutics

In related news, Director Simeon George bought 989,812 shares of the company's stock in a transaction on Wednesday, July 16th. The stock was bought at an average cost of $52.03 per share, with a total value of $51,499,918.36. Following the completion of the acquisition, the director owned 1,730,179 shares in the company, valued at approximately $90,021,213.37. This represents a 133.69% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 4.30% of the company's stock.

CRISPR Therapeutics Stock Up 2.2%

Shares of NASDAQ:CRSP opened at $61.67 on Friday. The company has a market cap of $5.61 billion, a P/E ratio of -11.36 and a beta of 1.81. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $71.13. The company has a 50-day moving average price of $57.59 and a 200 day moving average price of $46.91.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($1.29) EPS for the quarter, beating analysts' consensus estimates of ($1.47) by $0.18. The firm had revenue of $0.89 million during the quarter, compared to the consensus estimate of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The firm's revenue was up 72.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.49) earnings per share. Analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Analyst Ratings Changes

CRSP has been the subject of several recent research reports. HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday. JMP Securities reiterated a "market outperform" rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Piper Sandler reiterated an "overweight" rating and set a $105.00 target price on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Bank of America decreased their target price on shares of CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. Finally, Barclays increased their target price on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. Ten investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, CRISPR Therapeutics has an average rating of "Moderate Buy" and an average target price of $71.50.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.